指南与共识乳腺癌

中国晚期乳腺癌临床诊疗专家共识(2018版)

[Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma(2018)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

该共识由中国乳腺癌诊疗专家共识组制定,针对不可手术的局部晚期和复发或转移性乳腺癌,分析总结国内外诊断、治疗及预后研究数据,为临床医师提供参考。晚期乳腺癌5年生存率仅20%,总体中位生存时间2~3年,多线治疗后难治性乳腺癌缺乏标准推荐。

要点

  • 2015年中国乳腺癌新发病例约27.2万,死亡约7万余例。
  • 新发乳腺癌中约3%~10%确诊时即有远处转移,早期患者30%~40%可发展为晚期。
  • 晚期乳腺癌5年生存率仅20%,总体中位生存时间2~3年。

核心结论

  • 晚期乳腺癌目前虽难以治愈,但可通过新型治疗药物和优化治疗模式缓解症状、改善生活质量并延长生存时间。
  • 多线治疗后进展的难治性乳腺癌的治疗缺乏标准推荐。

研究设计与样本

  • 中国乳腺癌诊疗专家共识组对国内外不可手术的局部晚期和复发或转移性乳腺癌诊断、治疗及预后相关研究数据进行分析、总结和讨论后制定。

主要发现

  • 2015年中国乳腺癌新发约27.2万例,死亡约7万余例。
  • 每年新发乳腺癌中约3%~10%确诊时即有远处转移。
  • 早期患者中30%~40%可发展为晚期乳腺癌。
  • 晚期乳腺癌5年生存率仅20%,总体中位生存时间为2~3年。

临床怎么用

  • 供临床医师在晚期乳腺癌诊疗中参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignant tumor among women in the world. In 2015, there were about 272 000 new diagnosed cases and over 70 000 deaths of breast cancer in China. In new cases of breast cancer each year, about 3 to 10 percent have distant metastases at the time of diagnosis. Among the early-stage patients, 30%-40% will develop into advanced breast cancer. The 5-year survival rate of patients with the advanced breast cancer is only 20%, and the overall median survival is 2-3 years. Although advanced breast cancer is still difficult to cure at present, we can relieve the clinical symptoms, improve the quality of life and further prolong the survival time through development of new drugs and the optimization model of treatment. Patients with advanced breast cancer have their own particularity in the choice of treatment options. Moreover, there is no standard recommendation for the treatment of refractory breast cancer after multiline therapy. In order to offer reference for clinicians, the Chinese expert group has analyzed, summarized and discussed the related research data of diagnosis, treatment and prognosis of inoperable locally advanced breast cancer and recurrent or metastatic breast cancer, and developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018). 乳腺癌是全球女性最常见的恶性肿瘤,2015年中国新发乳腺癌病例约27.2万,死亡约7万余例。在每年新发乳腺癌病例中,约3%~10%的妇女在确诊时即有远处转移。早期患者中,30%~40%可发展为晚期乳腺癌,5年生存率仅20%,总体中位生存时间为2~3年。晚期乳腺癌目前虽难以治愈,但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存时间。晚期乳腺癌患者在治疗方案的选择方面有其特殊性,且多线治疗后进展的难治性乳腺癌的治疗缺乏标准推荐。中国乳腺癌诊疗专家共识组对不可手术的局部晚期和复发或转移性乳腺癌诊断、治疗及预后等方面国内外的相关研究数据进行分析、总结和讨论,制订出《中国晚期乳腺癌临床诊疗专家共识(2018版)》,以供临床医师参考。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma(2018)]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30293398. doi:10.3760/cma.j.issn.0253-3766.2018.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。